166 related articles for article (PubMed ID: 23375402)
1. When a thymic carcinoma "becomes" a GIST.
Rossi V; Donini M; Sergio P; Passalacqua R; Rossi G; Buti S
Lung Cancer; 2013 Apr; 80(1):106-8. PubMed ID: 23375402
[TBL] [Abstract][Full Text] [Related]
2. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
Buti S; Donini M; Sergio P; Garagnani L; Schirosi L; Passalacqua R; Rossi G
J Clin Oncol; 2011 Nov; 29(33):e803-5. PubMed ID: 21969494
[No Abstract] [Full Text] [Related]
3. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
4. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
5. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
6. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
7. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
8. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
9. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors, version 2.2014.
von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
[TBL] [Abstract][Full Text] [Related]
11. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
[No Abstract] [Full Text] [Related]
12. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
Caram MV; Schuetze SM
J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
[TBL] [Abstract][Full Text] [Related]
13. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
14. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a novel xenograft model of human gastrointestinal stromal tumor in mice.
Moriyama M; Shimada Y; Nagata T; Omura T; Sekine S; Matsui K; Yoshioka I; Okumura T; Sawada S; Yoshida T; Tsukada K
Anticancer Res; 2013 Jan; 33(1):175-81. PubMed ID: 23267143
[TBL] [Abstract][Full Text] [Related]
16. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Blay JY; Reichardt P
Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
18. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype.
Judson IR
J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449
[No Abstract] [Full Text] [Related]
19. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
20. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
